Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind comparative study of candesartan cilexetil + hydrochlorothiazide in mild/moderate essential hypertension
jRCT2080221017Phase 3
- Sponsor
- Takeda
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of candesartan cilexetil + hydrochlorothiazide in essential hypertension, sponsored by Takeda.
02
Drugs
candesartan cilexetil + hydrochlorothiazide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080221017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221017.